2020
Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States
Menzies NA, Bellerose M, Testa C, Swartwood N, Malyuta Y, Cohen T, Marks SM, Hill AN, Date AA, Maloney SA, Bowden SE, Grills AW, Salomon JA. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. American Journal Of Respiratory And Critical Care Medicine 2020, 202: 1567-1575. PMID: 32645277, PMCID: PMC7706168, DOI: 10.1164/rccm.202003-0526oc.Peer-Reviewed Original ResearchConceptsGlobal TB controlTB incidence trendsEnd TB StrategyTB controlTB casesIncidence trendsEconomic burdenWorld Health Organization's End TB StrategyTB incidence rateGlobal tuberculosis controlHigh-burden countriesTotal economic burdenMajor health benefitsBase case scenarioBirth countryTB incidenceTB epidemiologyTuberculosis controlTB StrategyIncidence rateHealthcare costsIncidence reductionInfection riskTuberculosisSubstantial health
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility
2012
Multidrug Resistance Among New Tuberculosis Cases
Hedt BL, van Leth F, Zignol M, Cobelens F, van Gemert W, Nhung NV, Lyepshina S, Egwaga S, Cohen T. Multidrug Resistance Among New Tuberculosis Cases. Epidemiology 2012, 23: 293-300. PMID: 22249242, PMCID: PMC3276714, DOI: 10.1097/ede.0b013e3182459455.Peer-Reviewed Original Research